TOURMALINE BIO INC.

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

14 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

07 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress

11 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board

08 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

03 Sep 2024 07:45:00 By Nasdaq GlobeNewswire

Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024

02 Aug 2024 16:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer

27 Jun 2024 08:05:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Jefferies Global Healthcare Conference

23 May 2024 07:10:00 By Nasdaq GlobeNewswire

Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial

16 May 2024 07:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

19 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Present at Upcoming Investor Conferences

27 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

01 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

29 Jan 2024 16:01:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Pricing of Public Offering of Common Stock

25 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Proposed Public Offering of Common Stock

24 Jan 2024 16:05:48 By Nasdaq GlobeNewswire

Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)

08 Jan 2024 07:00:00 By Nasdaq GlobeNewswire